InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,175.20
(
0.00%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.52
(
0.39%
)
Bitcoin
61,707.80
(
-0.17%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

BTH

Send PM Follow Ignore
Followers 16
Posts 4145
Boards Moderated 1
Alias Born 06/11/2010

BTH

Re: DonShimoda post# 4686

Thursday, 01/06/2011 9:32:02 PM

Thursday, January 06, 2011 9:32:02 PM

Post# of 80490
I guess you better hope that the SUCCEED trial has the majority of its patients NOT in the bone sarcoma category then. It seems like lipo and leiomy sarcomas have a fair response to the drug - what about the other several subsets that are being tested in the trial?

BTW, when I said "months", I was referring to some "statistical analysis" someone on another thread made (many people deemed this poster as highly 'credible') which had something to the effect of Ridaforolimus as having 100% increase versus the placebo-arm median. Which would have been well into the 6 months range.

How'd that work out?


BTW, what analysts do you know had Ridaforolimus beating the placebo in months, and not weeks? Has Berger ever stated he thought this as well?







Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up